Download Free Evaluation Of The 1954 Field Trial Of Poliomyelitis Vaccine Book in PDF and EPUB Free Download. You can read online Evaluation Of The 1954 Field Trial Of Poliomyelitis Vaccine and write the review.

Vaccines have saved more lives than any other single medical advance. Yet today only four companies make vaccines, and there is a growing crisis in vaccine availability. Why has this happened? This remarkable book recounts for the first time a devastating episode in 1955 at Cutter Laboratories in Berkeley, California, thathas led many pharmaceutical companies to abandon vaccine manufacture. Drawing on interviews with public health officials, pharmaceutical company executives, attorneys, Cutter employees, and victims of the vaccine, as well as on previously unavailable archives, Dr. Paul Offit offers a full account of the Cutter disaster. He describes the nation's relief when the polio vaccine was developed by Jonas Salk in 1955, the production of the vaccine at industrial facilities such as the one operated by Cutter, and the tragedy that occurred when 200,000 people were inadvertently injected with live virulent polio virus: 70,000 became ill, 200 were permanently paralyzed, and 10 died. Dr. Offit also explores how, as a consequence of the tragedy, one jury's verdict set in motion events that eventually suppressed the production of vaccines already licensed and deterred the development of new vaccines that hold the promise of preventing other fatal diseases.
The Immunization Safety Review Committee was established by the Institute of Medicine (IOM) to evaluate the evidence on possible causal associations between immunizations and certain adverse outcomes, and to then present conclusions and recommendations. The committee's mandate also includes assessing the broader societal significance of these immunization safety issues. While all the committee members share the view that immunization is generally beneficial, none of them has a vested interest in the specific immunization safety issues that come before the group. The committee reviews three immunization safety review topics each year, addressing each one at a time. In this fifth report in a series, the committee examines the hypothesis that exposure to polio vaccine contaminated with simian virus 40 (SV40), a virus that causes inapparent infection in some monkeys, can cause certain types of cancer.
In 1988, the World Health Organization launched a twelve-year campaign to wipe out polio. Thirty years and several billion dollars over budget later, the campaign grinds on, vaccinating millions of children and hoping that each new year might see an end to the disease. But success remains elusive, against a surprisingly resilient virus, an unexpectedly weak vaccine and the vagaries of global politics, meeting with indifference from governments and populations alike. How did an innocuous campaign to rid the world of a crippling disease become a hostage of geopolitics? Why do parents refuse to vaccinate their children against polio? And why have poorly paid door-to-door healthworkers been assassinated? Thomas Abraham reports on the ground in search of answers.
The compelling true story of Dr. Jonas Salk's quest to develop a vaccine for polio. In 1916, the United States was hit with one of the worst polio epidemics in history. The disease was a terrifying enigma: striking out of nowhere, it afflicted tens of thousands of children and left them—literally overnight—paralyzed. Others it simply killed. At the same time, a child named Jonas Salk was born.... When Franklin Delano Roosevelt was diagnosed with polio shortly before assuming the Presidency, Salk was given an impetus to study this deadly illness. After assisting in the creation of an influenza vaccine, Salk took up the challenge. His progress in combating the virus was hindered by the politics of medicine and by a rival researcher determined to discredit his proposed solution. But Salk's perseverance made history—and for close to seventy years his vaccine has saved countless lives, bringing humanity close to eradicating polio throughout the world. Splendid Solution chronicles Dr. Salk's race against time to achieve an unparalleled breakthrough that made him a cultural hero and icon of modern medicine.
This electronic version has been made available under a Creative Commons (BY-NC-ND) open access license. This book is available as an open access ebook under a CC-BY-NC-ND licence. Vaccinating Britain shows how the British public has played a central role in the development of vaccination policy since the Second World War. It explores the relationship between the public and public health through five key vaccines – diphtheria, smallpox, poliomyelitis, whooping cough and measles-mumps-rubella (MMR). It reveals that while the British public has embraced vaccination as a safe, effective and cost-efficient form of preventative medicine, demand for vaccination and trust in the authorities that provide it has ebbed and flowed according to historical circumstances. It is the first book to offer a long-term perspective on vaccination across different vaccine types. This history provides context for students and researchers interested in present-day controversies surrounding public health immunisation programmes. Historians of the post-war British welfare state will find valuable insight into changing public attitudes towards institutions of government and vice versa.
Through the lens of polio, Dóra Vargha looks anew at international health, communism and Cold War politics. This title is also available as Open Access.
When a waiting world learned on April 12, 1955, that Jonas Salk had successfully created a vaccine to prevent poliomyelitis, he became a hero overnight. Born in a New York tenement, humble in manner, Salk had all the makings of a twentieth-century icon--a knight in a white coat. In the wake of his achievement, he received a staggering number of awards and honors; for years his name ranked with Gandhi and Churchill on lists of the most revered people. And yet the one group whose adulation he craved--the scientific community--remained ominously silent. "The worst tragedy that could have befallen me was my success," Salk later said. "I knew right away that I was through--cast out." In the first complete biography of Jonas Salk, Charlotte DeCroes Jacobs unravels Salk's story to reveal an unconventional scientist and a misunderstood and vulnerable man. Despite his incredible success in developing the polio vaccine, Salk was ostracized by his fellow scientists, who accused him of failing to give proper credit to other researchers and scorned his taste for media attention. Even before success catapulted him into the limelight, Salk was an inscrutable man disliked by many of his peers. Driven by an intense desire to aid mankind, he was initially oblivious and eventually resigned to the personal cost--as well as the costs suffered by his family and friends. And yet Salk remained, in the eyes of the public, an adored hero. Based on hundreds of personal interviews and unprecedented access to Salk's sealed archives, Jacobs' biography offers the most complete picture of this complicated figure. Salk's story has never been fully told; until now, his role in preventing polio has overshadowed his part in co-developing the first influenza vaccine, his effort to meld the sciences and humanities in the magnificent Salk Institute, and his pioneering work on AIDS. A vivid and intimate portrait, this will become the standard work on the remarkable life of Jonas Salk.
Vaccines are among the most safe and effective public health interventions to prevent serious disease and death. Because of the success of vaccines, most Americans today have no firsthand experience with such devastating illnesses as polio or diphtheria. Health care providers who vaccinate young children follow a schedule prepared by the U.S. Advisory Committee on Immunization Practices. Under the current schedule, children younger than six may receive as many as 24 immunizations by their second birthday. New vaccines undergo rigorous testing prior to receiving FDA approval; however, like all medicines and medical interventions, vaccines carry some risk. Driven largely by concerns about potential side effects, there has been a shift in some parents' attitudes toward the child immunization schedule. The Childhood Immunization Schedule and Safety identifies research approaches, methodologies, and study designs that could address questions about the safety of the current schedule. This report is the most comprehensive examination of the immunization schedule to date. The IOM authoring committee uncovered no evidence of major safety concerns associated with adherence to the childhood immunization schedule. Should signals arise that there may be need for investigation, however, the report offers a framework for conducting safety research using existing or new data collection systems.